01—Abstract
Summary
Summary of the 8-K filed November 3, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. reported record third-quarter 2025 results and raised its 2025 financial guidance.
Total revenue for the quarter was $354.3 milliona, up 22% year-over-year from $290.1 million, driven by royalty revenue of $236.0 million, up 52% from $155.1 million. Net income was $175.2 million, compared to $137.0 million a year earlier, and GAAP diluted EPS was $1.43 versus $1.05. Non-GAAP diluted EPS was $1.72, compared to $1.27.
Adjusted EBITDA was $248.2 million, compared to $183.6 millionb in the prior-year quarter. Cash, cash equivalents and marketable securities totaled $702.0 million at September 30, 2025. For full-year 2025, the company now expects total revenue of $1,300 million to $1,375 million, royalty revenue of $850 million to $880 million, adjusted EBITDA of $885 million to $935 million, and non-GAAP diluted EPS of $6.10 to $6.50.
These ranges are each raised from the prior guidance issued August 5, 2025. The filing also discloses a CFO transition. Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will remain CFO until the earlier of the hiring of a successor or March 30, 2026, and then depart for a new professional opportunity.
The company has begun an external search for her successor. The filing states her departure is not the result of any disagreement with the auditors or the company. The company also disclosed a pending acquisition of Elektrofi, Inc. for $750 millionc in upfront consideration plus up to three $50 million milestone payments, expected to close in the fourth quarter of 2025.
02—Key points
Key Highlights
- Total revenue of $354.3 million in Q3 2025, up 22% year-over-year from $290.1 million, with royalty revenue of $236.0 million, up 52%
- Net income of $175.2 million (GAAP diluted EPS $1.43) versus $137.0 million (EPS $1.05) in Q3 2024
- Adjusted EBITDA of $248.2 million, compared to $183.6 million in Q3 2024
- 2025 guidance raised: total revenue $1,300-$1,375 million, royalty revenue $850-$880 million, adjusted EBITDA $885-$935 million, non-GAAP diluted EPS $6.10-$6.50
- CFO Nicole LaBrosse will depart after a transition period ending no later than March 30, 2026; an external search for a successor has begun
- Pending acquisition of Elektrofi, Inc. for $750 million upfront plus up to three $50 million milestones, expected to close in Q4 2025 subject to antitrust review
- Cash, cash equivalents and marketable securities of $702.0 million at September 30, 2025
03—Questions
Frequently Asked Questions
Why did Halozyme raise its 2025 guidance?
The company attributed the raise to continued strong performance of its core ENHANZE technology, with royalty revenue growth of approximately 50% expected for the full year. Revenue growth was driven primarily by royalties on partner products such as VYVGART Hytrulo, DARZALEX SC and Phesgo.
Who is leaving as CFO, and when?
Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue as CFO until the earlier of when a new CFO is hired or March 30, 2026, and then depart to pursue a new professional opportunity. The filing says her departure is not the result of any disagreement with the auditors or the company, and the company expects to enter into a transition and release agreement with her.
What is the Elektrofi acquisition?
Halozyme agreed in September 2025 to acquire Elektrofi, Inc., which has the ultra-high concentration microparticle technology Hypercon, for $750 million in upfront consideration plus up to three $50 million milestone payments tied to separate product regulatory approvals. The deal is expected to close in Q4 2025, subject to Hart-Scott-Rodino antitrust review and other customary conditions. Royalty contributions from Hypercon are projected to begin in 2030.
What drove the operating expense increases in the quarter?
Selling, general and administrative expense rose to $46.1 million from $41.2 million, primarily due to higher consulting and professional fees, including litigation costs in a patent infringement case and diligence costs for the Elektrofi acquisition. Cost of sales rose to $55.2 million from $49.4 million, mainly due to higher product sales, material scrap and labor allocation initiatives. Research and development expense decreased to $17.3 million from $18.5 million.
How much capital has been returned to shareholders through buybacks?
In June 2025 Halozyme began the third $250 million tranche of its $750 million share repurchase program approved in February 2024. As of September 30, 2025, $92.3 million had been used to repurchase approximately 1.7 million shares at an average price of $52.89 per share.
04—Continue